CHD1L and nasopharyngeal carcinoma: CHD1L is considered a cancer or prognostic biomarker, because its overexpression is usually associated with poor prognosis, such as in HCC [21], gastric cancer [22], bladder cancer [25], breast cancer [26], NSCLC [12], cholangiocarcinoma [20], and nasopharyngeal carcinoma [27].